Hormone replacement therapy, including estrogen, has been approved by the Food and Drug Administration for the treatment of patients with low estrogen levels, for example women experiencing menopause. A nonprofit group is pursuing research with the goal of gaining FDA approval for the use of estrogen as a gender-affirming treatment for transgender and gender-diverse patients.
In this article published in STAT News, Alex Keuroghlian, MD MPH notes, “It’s critically important to secure FDA approval for gender-affirming hormones and pubertal suppressants.” At a time when we are seeing various states limit access to gender-affirming care, FDA approval would represent an important step in making gender-affirming care accessible to those who need it.
Read More
Alex Keuroghlian, MD, MPH
Director, MGH Gender Identity Program
Associate Chief, Public and Community Psychiatry , MGH
Michele and Howard J Kessler Chair and Director, MGH Division of Public and Community Psychiatry
Director, Education and Training Programs at the Fenway Institute
Director, National LGBTQIA+ Health Education Center
Associate Professor of Psychiatry, Harvard Medical School
